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738Objective: The present meta-analysis aimed to compare the short-term safety and efficacy of drug-eluting stents
and coronary artery bypass graft surgery for patients with left main coronary artery disease.
Methods: Fourteen relevant studies were identified from 5 electronic databases. End points included mortality,
stroke, myocardial infarction, repeat revascularization, and major adverse cardiac and cerebrovascular events.
Results: Results indicate that all-cause mortality was similar between drug-eluting stents and coronary artery
bypass grafting at 30 days and at follow-up beyond 1 year. Likewise, the incidence of myocardial infarction
was similar between drug-eluting stents and coronary artery bypass grafting at 12 months and at follow-up be-
yond 1 year. However, drug-eluting stents were associated with a lower incidence of all-cause mortality at 12
months and a higher incidence of myocardial infarction at 30 days compared with coronary artery bypass graft-
ing. Drug-eluting stents were consistently associated with a higher incidence of repeat revascularization,
whereas coronary artery bypass grafting had a higher incidence of stroke. The incidence of major adverse car-
diac and cerebrovascular events was similar between the 2 groups at 30 days but higher for drug-eluting stents at
12 months and beyond.
Conclusions: Patients treated by drug-eluting stents in randomized controlled trials and observational studies in
the current literature are often a preselected subgroup with less complex lesions compared with the overall target
population. Results drawn from these studies should be viewed with caution. Coronary artery bypass grafting is
associated with a lower incidence of major adverse cardiac and cerebrovascular events at 1 year and beyond, and
thus should be regarded as the standard of treatment. However, drug-eluting stents may have a role for selected
patients with percutaneously amenable left main disease who are poor surgical candidates. (J Thorac Cardiovasc
Surg 2013;145:738-47)Earn CME credits at
http://cme.ctsnetjournals.org
Left main coronary artery disease (LMCAD) is defined as
a greater than 50% narrowing of the left main coronary ar-
tery and is found in approximately 5% of all patients who
undergo angiography.1 Without revascularization, patients
with LMCAD have a relatively poor prognosis, with
3-year survival as low as 34%.2 Previous studies have dem-
onstrated a clear survival benefit from revascularization
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The Journal of Thoracic and Cardiovascular Surgcomplexity and unfavorable characteristics often
associated with left main coronary artery lesions,
percutaneous coronary intervention (PCI) has been
traditionally deferred in preference for coronary artery
bypass grafting (CABG).4 However, with the evolution of
drug-eluting stents (DES) in recent years, there has been
a renewed interest in expanding the indication for PCI in pa-
tients with LMCAD.5 This shift in paradigm was reflected
in recent guidelines that recommended consideration of
PCI for selected patients with low risk of PCI-related com-
plications and increased risk of surgical complications.6
The recent European Society of Cardiology and the Euro-
pean Association for Cardiothoracic Surgery guidelines
on myocardial revascularization made level IA recommen-
dations for CABG in all patients with LMCAD, whereas
PCI was only recommended for selected patients with less
complex disease based on level II or III evidence.7
Despite encouraging results for DES from relatively
small observational studies with limited follow-up, there
was a lack of robust clinical data to compare DES with
CABG in patients with LMCAD.8 In view of this, a number
of randomized controlled trials have recently been pub-
lished to compare these 2 revascularization techniques.9-12ery c March 2013
Abbreviations and Acronyms
CABG ¼ coronary artery bypass grafting
CI ¼ confidence interval
DES ¼ drug-eluting stent
LMCAD ¼ left main coronary artery disease
MACCE ¼ major adverse cardiac and
cerebrovascular events
PCI ¼ percutaneous coronary intervention
RR ¼ relative risk
SYNTAX ¼ Synergy between Percutaneous
Coronary Intervention with Taxus and
Cardiac Surgery
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DThe aim of the present meta-analysis is to assess the short-
term outcomes after DES or CABG for patients with
LMCAD by using data from randomized and nonrandom-
ized comparative studies in the current literature. Specific
end points include components of major adverse cardiac
and cerebrovascular events (MACCE), including mortality,
stroke, myocardial infarction, and repeat revascularization.PATIENTS AND METHODS
Literature Search Strategy
Electronic searches were performed using Ovid Medline, Cochrane
Central Register of Controlled Trials, Cochrane Database of Systematic
Reviews, ACP Journal Club, and Database of Abstracts of Review of Effec-
tiveness from January 2000 to August 2011. To achieve the maximum sen-
sitivity of the search strategy and identify all studies, we combined the
terms surgery or coronary artery bypasswith angioplasty or stent or percu-
taneous coronary intervention and left main. The reference lists of all re-
trieved articles were reviewed for further identification of potentially
relevant studies. All relevant articles identified were assessed with applica-
tion of the inclusion and exclusion criteria.
Selection Criteria
Eligible comparative studies for the present meta-analysis included
those in which patients with angiographically proven LMCADwere treated
by DES or CABG. All forms of DES were included, as were patients who
underwent off-pump CABG. For studies that included patients with
LMCAD as a subset of patients who had other types of coronary artery dis-
eases, results for patients with LMCAD who underwent DES or CABG
were extractedwhen possible. Likewise, studies that includedDES as a pro-
portion of patients who underwent PCI were only included if outcomes
were available for the DES cohort. When centers have published duplicate
trials with accumulating numbers of patients or increased lengths of follow-
up, only the most complete reports were included for qualitative appraisal
at each time interval. To maintain the consistency of measured end points,
previous guidelines and definitions were used to assess short-term out-
comes when applicable.13,14 It is acknowledged that patient selection for
revascularization varied among institutions and sometimes within an
institution at different time periods. All publications were limited to
human subjects and in the English language. Abstracts, case reports,
conference presentations, editorials, and expert opinions were excluded.
Review articles are omitted because of potential publication bias and
possible duplication of results. Studies that included fewer than 20
patients or presented data with less than 12 months follow-up were also
excluded.The Journal of Thoracic and CaData Extraction and Critical Appraisal
All data were extracted from article texts, tables, and figures. When in-
sufficient data were available from publications, corresponding authors
were contacted to provide additional records. Two investigators (C.Q.C.
and T.D.Y.) independently reviewed each retrieved article. Discrepancies
between the 2 reviewers were resolved by discussion and consensus. The
final results were reviewed by the senior investigators.
Statistical Analysis
Meta-analysis was performed by combining the results of reported inci-
dences of mortality, stroke, myocardial infarction, repeat revascularization,
and MACCE. The relative risk (RR) was used as a summary statistic. In the
present study, both fixed and random effect models were tested. In a fixed ef-
fect model, it was assumed that treatment effect in each study was the same,
whereas in a random effect model, it was assumed that there were variations
between studies and the calculated ratios thus had more conservative value.15
Chi-square tests were used to study heterogeneity between trials. I2 statistic
was used to estimate the percentage of total variation across studies
due to heterogeneity rather than chance. I2 can be calculated as
I2¼ 100%3 (Qdf)/Q,withQdefinedasCochrane’s heterogeneity statistics
anddfdefined asdegrees of freedom.16An I2 value greater than50%was con-
sidered substantial heterogeneity. If there was substantial heterogeneity, the
possible clinical and methodological reasons for this were explored qualita-
tively. In the presentmeta-analysis, the results using the randomeffectsmodel
were presented to take into account the possible clinical diversity and meth-
odological variation among studies. Specific analyses considering confound-
ing factorswere not possible because rawdatawere not available.AllPvalues
were 2-sided. All statistical analysis was conducted with Review Manager
Version 5.1.2 (Cochrane Collaboration, Software Update, Oxford, UK).
RESULTS
Quantity and Quality of Trials
A total of 1018 references were identified through the 5
electronic database searches. After exclusion of duplicate
or irrelevant references, 570 potentially relevant articles
were retrieved for more detailed evaluation. After the selec-
tion criteria were applied, 16 comparative studies remained
for assessment. Manual search of the reference lists did not
identify any additional relevant studies. One study was
excluded because of duplicating patients at different
follow-up periods. One studywas excluded because primary
outcome data were not available. Of the 14 studies included
for final analysis in the present meta-analysis, 3 were from
randomized controlled trials and the remainder were from
observational studies, as summarized in Table 1.9-12,17-26
In these 14 studies, 5628 patients with LMCAD were
compared, including 2490 patients who were treated with
DES and 3138 patients who underwent CABG. Baseline
characteristics, patient selection, and follow-up periods var-
ied between studies, as summarized in Table 2.
Assessment of Mortality
All-cause mortality was not significantly different be-
tween DES and CABG at 30 days (2.3% vs 4.6%; RR,
0.57; 95% confidence interval [CI], 0.22-1.51; P ¼ .26;
I2 ¼ 54%). At 12 months, DES was found to be associated
with a significantly lower all-cause mortality (3.5% vs
5.7%; RR, 0.71; 95% CI, 0.54-0.95; P ¼ .02; I2 ¼ 0%).rdiovascular Surgery c Volume 145, Number 3 739
TABLE 1. Summary of comparative studies included in the present meta-analysis
First author Reference no. Location Study design Study period
No. of patients Follow-up (mo)
DES CABG DES CABG
Boudriot 8 Leipzig, Germany RCT 2003-2009 100 101 36
Cheng 17 Taiwan, China OS 2000-2007 94 216 16 27
Chieffo 18 Milan, Italy OS 2002-2004 107 142 62
Ghenim 19 Toulouse, France OS 2004-2007 105 106 12
Kang 20 Seoul, Korea OS 2003-2006 205 257 34
Kappetein 10 US/Europe Predefined subgroup analysis of RCT 2005-2007 357 348 36
Makikallio 21 Kajaani, Finland OS 2005-2007 49 238 12
Palmerini 22 Blogna, Italy OS 2003-2006 98 161 24
Park D-W 23 Seoul, Korea OS 2000-2006 784 690 62
Park S-J 11 Seoul, Korea RCT 2004-2009 300 300 24
Sanmartin 24 Vigo, Spain OS 2000-2005 96 245 16 38
Serruys 12 US/Europe Predefined subgroup analysis of RCT 2005-2007 357 348 12
Shimizu 25 Tokyo, Japan OS 2004-2007 64 89 19 26
Wu 26 Beijing, China OS 2003-2006 131 245 48
DES, Drug-eluting stent; CABG, coronary artery bypass grafting; RCT, randomized controlled trial; OS, observational study.
TABLE 2. Summary of baseline patient characteristics from comparative studies included in the present meta-analysis
First author
Age, y Male Ejection fraction (%) ACS Diabetes Off-pump
DES CABG DES CABG DES CABG DES CABG DES CABG CABG
Boudriot 66* 69* 72% 78% 65* 65* NR NR 40% 33% 46%
Cheng 68  10 67  9 75% 76% 56  17 56  20 76% 90% 35% 51% 8%
Chieffo 64  10 68  10 NR NR 52  10 52  11 NR NR 19% 23% 39%
Ghenim 81  3.5 80  3.5 64% 72% 26%z 17%z 70% 73% 31% 24% 0%
Kang 64  12 66  10 70% 74% 56  12 55  13 59% 68% 38% 44% 72%
Kappeteiny NR NR NR NR NR NR NR NR NR NR NR
Makikallio 72  10 70  9 59% 80% 55  12 54  11 53% 73% 20% 17% 52%
Palmerini 81* 78* 54% 66% 50* 53* 77% 52% 31% 26% 21%
Park D-W 63  11 64  9 71% 72% 60  11 56  12 63% 76% 32% 37% 42%
Park S-J 62  10 63  10 76% 77% 62  8 61  9 47% 54% 34% 30% 64%
Sanmartin 66  13 66  10 81% 87% 33%z 24%z 51% 62% 19% 32% NR
Shimizu 71  7 70  9 81% 85% 6%x 12%x 33% 48% 65% 54% 91%
Wu 62  11 64  9 76% 83% 60  12 59  12 68% 69% 27% 29% 22%
LM only LMþ1 vessel LMþ2 vessels LMþ3 vessels SYNTAX score Euroscore
DES CABG DES CABG DES CABG DES CABG DES CABG DES CABG
Boudriot 28% 29% 35% 27% 26% 28% 11% 17% 24* 23* 2.4* 2.6*
Cheng 3% 1% 10% 4% 21% 17% 66%k 77%k NR NR 6.9  3.5 6.4  3.3
Chieffo NR NR NR NR NR NR NR NR 28.8  10.4 29.4  5.8 4.4  3.6 4.3  3.4
Ghenim NR NR 31% 5% 40% 13% 30% 82% NR NR 8* 7*
Kang 15% 6% 32% 9% 21% 25% 33% 60% NR NR 4.2  3.9 5.6  3.8
Kappeteiny 12% 14% 19% 20% 31% 30% 38% 35% NR NR NR NR
Makikallio 69% NR NR NR NR NR NR NR NR NR 7.7  7.5 5.2  4.4
Palmerini NR NR NR NR NR NR NR NR NR NR 8* 7*
Park D-W NR NR NR NR NR NR NR NR NR NR NR NR
Park S-J 9% 11% 17% 18% 34% 30% 41% 41% 24.4  9.4 25.8  10.5 2.6  1.8 2.68  1.9
Sanmartin NR NR NR NR NR NR NR NR NR NR 4.0  2.5 3.9  3.0
Shimizu 0% 1% 28% 8% 23% 29% 48% 62% NR NR 2.7* 4.9*
Wu 9% 3% 18% 4% 38% 26% 35% 67% NR NR 4.2  2.7 4.3  2.4
ACS, Acute coronary syndrome;DES, Drug-eluting stent;CABG, coronary artery bypass grafting; LM, left main; SYNTAX, Synergy between Percutaneous Coronary Intervention
with Taxus and Cardiac Surgery;NR, not reported. *Median values. yData are the same as those of Serruys and colleagues.12 zProportion of patients with ejection fraction<50%.
xProportion of patients with ejection fraction<40%. kIncluding disease in ramus.
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FIGURE 1. Forest plot of the RR of all-cause mortality after DES versus CABG for LMCAD. The estimate of the RR of each trial corresponds to the
middle of the squares, and the horizontal line shows the 95% CI. On each line, the numbers of events as a fraction of the total number randomized are
shown for both treatment groups. For each subgroup, the sum of the statistics, along with the summary RR, is represented by the middle of the solid
diamonds. A test of heterogeneity between the trials within a subgroup is given below the summary statistics. CI, Confidence interval; CABG, coronary
artery bypass grafting; DES, drug-eluting stent.
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ity at follow-up beyond 12 months (8.5% vs 10.5%;
RR, 0.84; 95% CI, 0.70-1.02; P¼ .08; I2¼ 0%). These re-
sults are summarized in Figure 1.
Assessment of Stroke
Nine studies reported the incidence of stroke and demon-
strated a lower risk after DES compared with CABG at 30
days (0.5% vs 3.4%; RR, 0.28; 95% CI, 0.11-0.73;
P ¼ .009; I2 ¼ 0%), 12 months (0.4% vs 2.1%; RR,The Journal of Thoracic and Ca0.25; 95% CI, 0.09-0.68; P ¼ .007; I2 ¼ 0%), and
follow-up beyond 12 months (1.2% vs 3.3%; RR, 0.39;
95% CI, 0.20-0.76; P ¼ .005; I2 ¼ 0%). The definition
of stroke included transient ischemic attacks in one study18
but was excluded in others.10,11,21,25 These results are
summarized in Figure 2.
Assessment of Myocardial Infarction
Myocardial infarction was more likely to occur after
DES compared with CABG at 30 days (2.9% vs 1.1%;rdiovascular Surgery c Volume 145, Number 3 741
FIGURE 2. Forest plot of the RR of stroke after DES versus CABG for LMCAD. The estimate of the RR of each trial corresponds to the middle of the
squares, and the horizontal line shows the 95% CI. On each line, the numbers of events as a fraction of the total number randomized are shown for both
treatment groups. For each subgroup, the sum of the statistics, along with the summary RR, is represented by the middle of the solid diamonds. A test of
heterogeneity between the trials within a subgroup is given below the summary statistics. CI, Confidence interval; CABG, coronary artery bypass grafting;
DES, drug-eluting stent.
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DRR, 2.56; 95% CI, 1.21-5.40; P ¼ .01; I2 ¼ 43%), but no
significant difference was reported at 12 months (2.8% vs
2.3%; RR, 1.21; 95% CI, 0.69-2.12; P ¼ .51; I2 ¼ 0%)
and at follow-up beyond 12 months (3.8% vs 2.3%; RR,
1.51; 95% CI, 0.93-2.43; P ¼ .09; I2 ¼ 0%). All studies
except for 2 defined postprocedural myocardial infarction
as an elevation of serologic cardiac biomarkers with or
without ECG changes, which is consistent with previous
guidelines.13,14 Chieffo and colleagues18 and Park and col-
leagues23 diagnosed perioperative myocardial infarction in
all patients who developed new pathologic Q-waves, with
or without changes in cardiac enzymes. According to this
definition, 10 of 107 patients (9.3%) had in-hospital myo-
cardial infarctions after DES and 37 of 142 patients
(26.1%) had myocardial infarctions after CABG in the re-
port by Chieffo and colleagues.18 Because of the significant
variation of definition in these 2 studies, outcomes of myo-
cardial infarction and MACCE were excluded from the742 The Journal of Thoracic and Cardiovascular Surgpresent meta-analysis. These results are summarized in
Figure 3.
Assessment of Revascularization
The repeat revascularization rate was significantly higher
after DES compared with CABG at 12 months (11.9% vs
3.5%; RR, 3.41; 95% CI, 2.59-4.51; P < .00001;
I2 ¼ 42%), 24 months (15.0% vs 7.7%; RR, 2.23; 95%
CI, 1.61-3.09; P<.00001; I2¼ 0%), and follow-up beyond
2 years (20.8% vs 7.7%; RR, 3.01; 95% CI, 2.34-3.88;
P< .00001; I2 ¼ 68%). These results are summarized in
Figure 4.
Assessment of Major Adverse Cardiac and
Cerebrovascular Events
From the relevant studies identified from the current
literature, MACCE was most commonly defined as a com-
bined incidence of mortality, stroke, myocardial infarction,ery c March 2013
FIGURE 3. Forest plot of the RR ofMI after DES versus CABG for LMCAD. The estimate of the RR of each trial corresponds to the middle of the squares,
and the horizontal line shows the 95% CI. On each line, the numbers of events as a fraction of the total number randomized are shown for both treatment
groups. For each subgroup, the sum of the statistics, along with the summary RR, is represented by the middle of the solid diamonds. A test of heterogeneity
between the trials within a subgroup is given below the summary statistics. CI, Confidence interval; CABG, coronary artery bypass grafting; DES,
drug-eluting stent.
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all studies, those studies that excluded stroke9 or repeat re-
vascularization19 or included repeat hospitalization21 as
part of MACCE were excluded from analysis. The remain-
ing 7 studies demonstrated a similar incidence of MACCE
after DES or CABG at 30 days (3.1% vs 5.3%; RR, 0.65;
95% CI, 0.39-1.09; P ¼ .10; I2 ¼ 60%), but a significantly
higher incidence of MACCE after DES compared with
CABG at 12 months (16.4% vs 11.8%; RR, 1.53; 95%
CI, 1.23-1.89; P¼ .0001; I2¼ 18%) and follow-up beyond
12 months (25.9% vs 19.5%; RR, 1.57; 95%CI, 1.29-1.89;
P<.00001; I2 ¼ 10%). These results are summarized in
Figure 5.
DISCUSSION
Since the introduction of percutaneous revascularization
techniques in the 1990s, there has been a paradigm shiftThe Journal of Thoracic and Catoward catheterization-based treatment strategies as an al-
ternative to CABG in the management of coronary artery
disease. However, patients with LMCAD have traditionally
been considered to have improved outcomes after surgical
intervention compared with PCI.27 Recent improvements
in percutaneous technology in the form of DES have re-
duced restenosis rates and mortality, repeat revasculariza-
tion, and MACCE compared with bare metal stents.28
Despite a heightened interest in the comparative outcomes
of DES versus CABG for patients with LMCAD, the
choice for the optimal revascularization technique remains
controversial.
In the present meta-analysis, significant heterogeneity
was identified among 3 randomized-controlled trials and 9
observational studies. DES included a number of different
stents, most commonly sirolimus- and paclitaxel-eluting
stents. For patients who underwent CABG, off-pumprdiovascular Surgery c Volume 145, Number 3 743
FIGURE 4. Forest plot of the RR of repeat revascularization after DES versus CABG for LMCAD. The estimate of the RR of each trial corresponds to the
middle of the squares, and the horizontal line shows the 95%CI. On each line, the numbers of events as a fraction of the total number randomized are shown
for both treatment groups. For each subgroup, the sum of the statistics, along with the summary RR, is represented by the middle of the solid diamonds. A test
of heterogeneity between the trials within a subgroup is given below the summary statistics.CI, Confidence interval;CABG, coronary artery bypass grafting;
DES, drug-eluting stent.
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lection criteria varied between institutions, including 1
study that only included patients who were aged 75 years
or more.19 The definitions of measured end points also dif-
fered between institutions, but generally included compo-
nents of MACCE, including mortality, stroke, myocardial
infarction, and repeat revascularization.
Results from the selected studies in the present meta-
analysis demonstrated lower all-cause mortality rates at
12 months after DES compared with CABG. Patients
who underwent CABG were also more likely to have
a stroke, whereas patients who underwent DES were
more likely to require repeat revascularization. Myocardial
infarction was found to be less likely after CABG at 30744 The Journal of Thoracic and Cardiovascular Surgdays, but this difference was no longer significant at 12
months and beyond. There was a trend toward fewer
MACCE after DES compared with CABG at 30 days,
but this finding was reversed at 12 months and at
follow-up beyond 12 months, when patients who had
CABG were found to be significantly less likely to have
MACCE.
Contrary to previous reports, data from the present
meta-analysis demonstrated a lower all-cause mortality
rate for patients who underwent DES compared with
CABG at 12 months and a trend toward lower all-cause
mortality beyond 1 year follow-up.29 A number of poten-
tial contributing factors may explain this unexpected find-
ing. First, all-cause mortality rates may be due to patientery c March 2013
FIGURE 5. Forest plot of the RR of MACCE after DES versus CABG for LMCAD. The estimate of the RR of each trial corresponds to the middle of the
squares, and the horizontal line shows the 95% CI. On each line, the numbers of events as a fraction of the total number randomized are shown for both
treatment groups. For each subgroup, the sum of the statistics, along with the summary RR, is represented by the middle of the solid diamonds. A test of
heterogeneity between the trials within a subgroup is given below the summary statistics. CI, Confidence interval; CABG, coronary artery bypass grafting;
DES, drug-eluting stent; MACCE, major adverse cardiac and cerebrovascular events.
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specific mortality was examined, none of the individual
studies or their accumulated results at 30-days, 12 months,
and beyond 12 months were significantly different after
DES compared with CABG.10,17,18,20 Second, differences
in baseline characteristics and the patient selection
process may have resulted in a biased patient cohort
who underwent CABG. From the data presented in
Table 2, it can be seen that patients were generally more
likely to present with acute coronary syndrome before
CABG compared with DES. In addition, none of the indi-
vidual randomized controlled trials or any of their accu-
mulated results at 30 days, 12 months, and at follow-up
beyond 12 months demonstrated any significant differ-
ences in all-cause survival.9-12The Journal of Thoracic and CaIt should be acknowledged that results from the present
meta-analysis were collected from a highly selected group
of patients treated in tertiary referral centers, and their out-
comes may not reflect the target population. LMCAD in-
cludes a wide spectrum of anatomic features that may or
may not be associated with concurrent multivessel disease.
Previous studies have shown that 70% to 90% of patients
with LMCAD will present with multivessel coronary artery
disease.12,30 From the summarized data demonstrated in
Table 2, it seems that patients with LMCAD and concomi-
tant multivessel disease may be underrepresented in the
comparative studies included in the present meta-analysis.
In all the observational studies, patients were more likely
to undergo CABG if they were found to have LMCAD
in combination with multivessel disease.9,17,19,20,25,26rdiovascular Surgery c Volume 145, Number 3 745
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were screened before randomization and allocated to
a parallel nested registry if deemed to have complex
anatomic features.10,12 Although there are limited data to
provide long-term outcomes for subgroups of patients
with concurrent multisvessel disease, results from 2 large
randomized controlled trials report a trend toward better
outcomes for patients with 2- and 3-vessel disease after
CABG compared with DES. It has been demonstrated that
the anatomic complexity of coronary artery disease quanti-
fied by the Synergy between Percutaneous Coronary Inter-
vention with Taxus and Cardiac Surgery (SYNTAX) score
is less influential on patient outcome after CABG compared
with DES.31
The SYNTAX trial is the largest randomized controlled
trial to compare DES with CABG, involving 1800 patients
with previously untreated 3-vessel disease or LMCAD.10,12
Results from the predefined subgroup of randomized
patients with LMCAD who underwent DES (n ¼ 357) or
CABG (n ¼ 348) indicated a similar incidence of
MACCE (15.8% vs 13.7%, P ¼ .44) at 12 months.12 Pa-
tients who underwent DES were more likely to require re-
peat revascularization (11.8% vs 6.5%, P ¼ .02) but had
a decreased risk of stroke (0.3% vs 2.7%, P¼ .01), similar
to the results of the present meta-analysis. These findings
were repeated at 3-year follow-up, but there is an emerging
trend toward a higher incidence of myocardial infarction
(8.9% vs 4.1%, P ¼ .14) and MACCE (26.8% vs
22.3%, P ¼ .20) for patients treated by DES compared
with CABG.10 Indeed, MACCE was found to be signifi-
cantly higher in patients treated by DES in the entire ran-
domized cohort (28.0% vs 20.2%, P< .001), and stroke
was no longer significantly different at 3 years (2.0% vs
3.4%, P¼ .07). Perhaps more important, it should be high-
lighted that only a minor proportion (1800/4337) of patients
assessed for eligibility were eventually randomized in this
‘‘all-comers’’ trial. Of the patients who were excluded
from randomization, 198 patients who underwent DES
and 1077 patients who underwent CABG were included
in a separate nested registry, which found higher incidences
of MACCE (20.4% vs 8.8%), mortality (7.3% vs 2.5%),
myocardial infarction (4.2% vs 2.5%), and repeat revascu-
larization (12.0% vs 3.0%) for patients whowere treated by
DES at 12 months. The main reason for registry allocation
to CABG (70.9%) was the complexity of anatomy, whereas
the main reason for PCI allocation was increased comorbid-
ity (70.7%). Likewise, a randomized controlled trial by
Boudriot and colleagues9 compared 100 patients who un-
derwent DES with 101 patients who underwent CABG.
The authors reported similar combined incidences of
cardiac death, myocardial infarction, and repeat revascular-
ization at 12 months (19.0% vs 13.9%, P ¼ .19 for
non-inferiority). However, of the 229 patients with LMCAD
who were considered ineligible for randomization,746 The Journal of Thoracic and Cardiovascular Surga significantly lower incidence of MACCE was reported
for CABG compared with DES and conservative therapy
(17.8% vs 27.5% vs 43%). Although reasons for exclusion
from randomization differ between trials, it should be em-
phasized that results derived from patients selected for ran-
domization in these tertiary referral centers do not
necessarily represent the target population of patients diag-
nosed with LMCAD, especially those with more complex
disease. Finally, all 3 randomized controlled trials identified
from the current literature used non-inferiority tests for sta-
tistical analysis with relatively wide margins, and none of
the studies were sufficiently powered for analysis of indi-
vidual end points.9-12CONCLUSIONS
Results from the present meta-analysis found a higher in-
cidence of MACCE for patients who underwent DES com-
pared with CABG at 12 months and beyond. Patients were
also more likely to require repeat revascularization after
DES compared with CABG but were less likely to have
a stroke and had a lower all-cause mortality rate at 12
months. Randomized controlled trials in the current litera-
ture seem to exclude a large proportion of patients from ran-
domization and analysis, and patients who are deemed
ineligible for randomization are more likely to undergo
CABG with superior outcomes compared with PCI. Over-
all, current evidence suggests that CABG is still superior
to DES for the majority of patients with LMCAD, espe-
cially for those with complex anatomy and multivessel dis-
ease at follow-up beyond 12 months. However, there is now
evidence that DES may have an important clinical role for
selected patients with percutaneously amenable left main
disease who are poor surgical candidates. Future studies
should aim to recruit larger number of patients in well-
designed randomized trials with sufficient follow-up and
complete analysis of all MACCE. Specifically, 5-year
follow-up data from the SYNTAX trial and the upcoming
Evaluation of Xience Prime versus Coronary Artery Bypass
Surgery for Effectiveness of Left Main Revascularization
(EXCEL) trial32 may offer valuable insight to long-term
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